BioMed X, an independent research organization based on the campus of the University of Heidelberg, Germany, announced that it has signed a research collaboration with Sanofi to develop an artificial intelligence (AI) computational platform for predicting the efficacy of first-in-class drugs using a virtual patient population. The initial proof-of-concept phase of the collaboration will focus on immune-induced chronic diseases including atopic dermatitis (AD) and inflammatory bowel disease (IBD).
“In the past two years, we have gained significant experience in the field of artificial intelligence through our strategic partnership with AION Labs in Israel,” noted Christian Tidona, founder and managing director of BioMed X. “Our new collaboration with Sanofi allows us to extend our expertise in data science and artificial intelligence in Heidelberg, as we have developed an ideal incubation environment for biomedical innovation at the interface between academia and industry.”
The use of artificial intelligence and machine learning in drug discovery and development is rapidly increasing in the biopharmaceutical industry. Virtual patient groups and digital twins seek to leverage large data sets from previous research to help identify drug candidates that should be prioritized for further development with a focus on reducing the high costs associated with the current industry failure rate of 90% for clinical drug candidates. development.
By collaborating with BioMed X, Sanofi is looking to leverage the research institute model of engaging early-career scientists from leading academic centers to serve as early-stage incubators for innovation approaches to biomedical research and development. BioMed X says it works “at the interface between academia and industry” to conduct biomedical research. The research partners are the true “Who’s Who” in the pharmaceutical sector worldwide including Boehringer Ingelheim, Johnson & Johnson, Merck, Roche and AbbVie, among others. She currently has ongoing research collaborations in the fields of oncology, immunology, neuroscience, and platform technologies.
For its work with Sanofi, BioMed X will work with the pharmaceutical company to co-select a team of scientists, using the current BioMed X recruitment model, which includes a global call for applications to be on the team followed by a five-day innovation bootcamp. The winning team on the project will be hosted for up to five years at the BioMed X Institute at the University of Heidelberg’s Life Sciences campus to begin developing the AI capabilities needed to accurately test candidate drugs in virtual patient populations using data provided by Sanofi.
“Identifying high-quality clinical candidates for treating patients with unmet needs is among the most rewarding parts of the research and development process,” said Frank Nestle, Sanofi’s Global Head of Research and Chief Scientific Officer. “This ground-breaking research collaboration will allow us to partner with scientists with unique computational skills and diverse capabilities that will help us achieve our goals of delivering biotherapies to patients with chronic inflammatory diseases. This collaboration will be instrumental to advance our core mission of transforming drug discovery and development through the application of modeling and simulation. based on artificial intelligence.